ATYR PHARMA, INC. (NASDAQ:LIFE) Files An 8-K Regulation FD Disclosure

ATYR PHARMA, INC. (NASDAQ:LIFE) Files An 8-K Regulation FD Disclosure

Story continues below

Item 7.01 Regulation FD Disclosure.

aTyr Pharma, Inc. (the Company) intends to use an investor
presentation to conduct meetings with investors, stockholders and
analysts and at investor conferences, and which the Company
intends to place on its website.A copy of the presentation
materials is attached hereto as Exhibit 99.1.The Company does not
undertake to update the presentation materials.

The information under this Item 7.01, including Exhibit 99.1, is
being furnished and shall not be deemed filed for the purposes of
Section 18 of the Securities and Exchange Act of 1934, as
amended, or the Exchange Act, or otherwise subject to the
liabilities of that section, nor shall they be deemed
incorporated by reference into any filing under the Securities
Act of 1933, as amended, or the Exchange Act, except as expressly
set forth by specific reference in such filing.

Item 9.01 Exhibits.

(d)Exhibits

Exhibit No.

Description

99.1

Corporate Presentation Materials of aTyr Pharma, Inc.
dated January 2017


About ATYR PHARMA, INC. (NASDAQ:LIFE)

aTyr Pharma, Inc. is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B. The Company is developing Resolaris, an intravenous protein therapeutic for the treatment of rare myopathies with an immune component (RMICs). The Company is investigating Resolaris in patients with LGMD2B. The Company is conducting approximately three open label trials in patients with early onset FSHD, in adult patients with FSHD or LGMD2B and a long-term extension study in adult patients with FSHD. The Company has not generated any revenues.

ATYR PHARMA, INC. (NASDAQ:LIFE) Recent Trading Information

ATYR PHARMA, INC. (NASDAQ:LIFE) closed its last trading session up +0.05 at 2.50 with 52,879 shares trading hands.

An ad to help with our costs